Ischemia-modified albumin and advanced oxidation protein products as potential biomarkers of protein oxidation in Alzheimer's disease

Geriatrics and Gerontology International

Volumn 15, Issue 7, 2015, Pages 872-880

  Altunoglu, Esma ^a   Guntas, Gulcan ^c   Erdenen, Fusun ^a   Akkaya, Esen ^a   Topac, Ibrahim ^b   Irmak, Hulya ^d   Derici, Himmet ^b   Yavuzer, Hakan ^d   Gelisgen, Remise ^d   Uzun, Hafize ^d  

^a Istanbul Education and Research Hospital   (Turkey)

^b Kirklareli University School of Health ^*  (Turkey)

^c KIRKLARELI UNIVERSITY   (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Advanced oxidation protein products; Alzheimer's disease; Ischemia modified albumin; Oxidative stress; Prooxidant antioxidant balance

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; BIOLOGICAL MARKER; FERRIC REDUCING ANTIOXIDANT POWER; ISCHEMIA MODIFIED ALBUMIN; PROOXIDANT ANTIOXIDANT BALANCE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ISCHEMIA-MODIFIED ALBUMIN; SERUM ALBUMIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HEALTH STATUS; HUMAN; MALE; OXIDATION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN OXIDATION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; BLOOD; MIDDLE AGED; OXIDATION REDUCTION REACTION; PHYSIOLOGY; RECEIVER OPERATING CHARACTERISTIC; VERY ELDERLY;

ADVANCED OXIDATION PROTEIN PRODUCTS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOMARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; ROC CURVE; SERUM ALBUMIN;

EID: 84933677738     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/ggi.12361     Document Type: Article

References (41)

1. Ramachandran TS. Alzheimer's disease imaging. E-medicine.medscape/article/336281 overview up to date: Now 7, 2013.
2. Yamamoto Y. Current topics about mild cognitive impairment. Seishin Shinkeigaku Zasshi 2011; 113: 584-592.
3. Marcues F, Sousa JC, Sousa N, Palha JA. Blood-brain-barriers in aging and in Alzheimer's disease. Mol Neurodegener 2013; 8: 38-45.
4. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007; 3: 186-191.
5. Shakir T, Coulibaly AY, Kehoe PG. An exploration of the potential mechanisms and translational potential of five medicinal plants for applications in Alzheimer's disease. Am J Neurodegener Dis 2013; 2: 70-88.
6. Sotiropoulos I, Catania C, Pinto LG etal. Stress acts cumulatively to precipitate Alzheimer's disease-like tau pathology and cognitive deficits. J Neurosci 2011; 31: 7840-7847.
7. Maltsev AV, Davidchenko NV, Uteshev VK etal. Intensive protein synthesis in neurons and phosphorylation of beta-amyloid precursor protein and tau-protein are triggering factors of neuronal amyloidosis and Alzheimer's disease. Biomed Khim 2013; 59: 144-170.
8. Galasko D, Montine TJ. Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark Med 2010; 4: 27-36.
9. Yan LJ, Xiao M, Chen R, Cai Z. Metabolic dysfunction of astrocyte: an initiating factor in beta-amyloid pathology? Aging Neurodegener 2013; 1: 7-14.
10. Grimm MO, Zinser EG, Grosgen S etal. Amyloid precursor protein (APP) mediated regulation of ganglioside homeostasis linking Alzheimer's disease pathology with ganglioside metabolism. PLoS One 2012; 7: 34-95.
11. Padurariu M, Ciobica A, Lefter R, Serban IL, Stefanescu C, Chirita R. The oxidative stress hypothesis in Alzheimer's disease. Psychiatr Danub 2013; 25: 401-409.
12. Golden TR, Hinerfeld DA, Melov S. Oxidative stress and aging: beyond correlation. Aging Cell 2002; 1: 117-123.
13. Su B, Wang X, Nunomura A etal. Oxidative stress signaling in Alzheimer's disease. Curr Alzheimer Res 2008; 5: 525-532.
14. Shulman RG, Rothman DL, Behar KL, Hyder F. Energetic basis of brain activity: implications for neuroimaging. Trends Neurosci 2004; 27: 489-495.
15. Marlatt MW, Lucassen PJ, Perry G, Smith MA, Zhu X. Alzheimer's disease: cerebrovascular dysfunction, oxidative stress and advanced clinical therapies. J Alzheimer Dis 2008; 15: 199-210.
16. Puertas MC, Martinez-Martos JM, Cobo MP, Carrera MP, Mayas MD, Ramirez-Exposito MJ. Plasma oxidative stress parameters in men and women with early stage Alzheimer's type dementia. Exp Gerontol 2012; 47: 625-630.
17. Kalaria RN. Vascular factors in Alzheimer's disease. Int Psychogeriatr 2003; 15: 47-52.
18. Kalaria RN. Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev 2010; 68: 574-587.
19. McKhann G, Drachman D, Folstein M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDAwork group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-944.
20. Folstein MF, Folstein JE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-199.
21. Morris JC. The Clinical Dementia Rating (CDR): current vision and scoring rules. Neurology 1993; 43: 2412-2414.
22. Lowton NP, Brody EM. Assessment of older people self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179-186.
23. Gelisgen R, Genc H, Kayali R etal. Protein oxidation markers in women with and without gestational diabetes mellitus: a possible relation with paraoxonase activity. Diabetes Res Clin Pract 2011; 94: 404-409.
24. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 1996; 239: 70-76.
25. Alamdari DH, Mobarhan MG, Tavallaie S etal. Prooxidantantioxidant-balance as a new risk factor in patients with angiographically defined coronary artery disease. Clin Biochem 2008; 41: 375-380.
26. Elidağ HY, Bulbuller N, Eren E etal. Ischemia-modified albumin: could it be a new oxidative stress biomarker for colorectal carcinoma. Gut Liver 2013; 7: 675-680.
27. Devasagayam TPA, Tilak JC, Boloor KK, Ketaki SS, Ghaskadbi SS, Lele RD. Free radicals and antioxidants in human health: current status and future prospects. J Assoc Physicians India 2004; 52: 794-810.
28. Ma S, Jin Y, Hu W, Bai F, Xu W, Yu W. Evaluation of ischemia-modified albumin and C-reactive Protein in type 2 diabetics with and without ketosis. Biomark Insights 2012; 7: 19-26.
29. Gündüz A, Turedi S, Mentese A etal. Ischemia-modified albumin levels in cerebrovascular accidents. Am J Emerg Med 2008; 26: 874-878.
30. Kumar A. Ischemia-modified albumin: its diagnostic implications and shortfalls. J Biomed Sci 2012; 1: 2-4.
31. Can M, Varlibas F, Güven B, Akhan O, Yuksel GA. Ischemia modified albumin and plasma oxidative stress markers in Alzheimer's disease. Eur Neurol 2013; 69: 377-380.
32. Korkmaz GG, Altunoglu E, Civelek S etal. The association of oxidative stress markers with conventional risk factors in the metabolic syndrome. Metabolism 2013; 62: 828-835.
33. Cervellati C, Romani A, Seripa D etal. Oxidative balance, homocysteine and uric acid levels in older patients with late onset Alzheimer's disease or vascular dementia. J Neurol Sci 2014; 337: 156-161.
34. Cervellati C, Romani A, Seripa D etal. Systemic oxidative stress and conversion to dementia of elderly patients with mild cognitive impairment. Biomed Res Int 2014; 2014: 309507. doi: 10.1155/2014/309507.
35. Bergamini CM, Gambetti S, Dondi A, Cervellati C. Oxygen reactive species and tissue damage. Curr Pharm Des 2004; 10: 1611-1626.
36. Aliev G, Priyadarshini M, Reddy VP etal. Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer's disease. Curr Med Chem 2014; 21: 2208-2217.
37. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
38. Matsuoka Y, Picciano M, La Francois J, Duff K. Fibrillar beta-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. Neuroscience 2001; 104: 609-613.
39. Wirz KT, Keitel S, Swaab DF, Verhaagen J, Bossers K. Early molecular changes in Alzheimer's disease: can we catch the disease in its presymptomatic phase? J Alzheimers Dis 2014; 38: 719-740.
40. Pulido R, Jimenez-Escrig A, Orensanz L etal. Study of plasma antioxidant status in Alzheimer's disease. Eur J Neurol 2005; 12: 531-535.
41. Sekler A, Jimenez JM, Rojo L etal. Cognitive impairment and Alzheimer's disease: links with oxidative stress and cholesterol metabolism. Neuropsychiatr Dis Treat 2008; 4: 715-722.